Event Highlights

Prof Andrew Gennery is a Professor of Paediatric Immunology and Haematopoietic Stem Cell Transplantation at the University of Newcastle upon Tyne and an Honorary Consultant for the Northern Supra-Regional Bone Marrow Transplant Unit for SCID and related disorders, at the Great North Children’s Hospital in Newcastle upon Tyne. His foundational research includes a postdoctoral year at Necker Hospital in Paris, where he contributed to the discovery of Cytidine Deaminase, a key gene in class switch recombination and somatic hypermutation. Having served as a consultant in Newcastle for 23 years, Prof Gennery’s research interests include immunoreconstitution post-haematopoietic stem cell transplant for primary immunodeficiency, long-term outcomes of transplantation (particularly in Chronic Granulomatous Disease and Severe Combined Immunodeficiency), and the treatment of DNA repair disorders. He has adapted new T-cell depletion methods for primary immunodeficiency patients and established extracorporeal photopheresis for treatment of children with graft versus host disease, uncovering significant mechanistic insights into its action. Prof Gennery has held prominent leadership roles, including chairing the ESID/EBMT Inborn Errors Working Party group, the ESID Clinical Working Party, the ERN-RITA Guidelines Working Party, and the CIBMTR Primary Immune Deficiencies, Inborn Errors of Metabolism and other NMMD Working Committee. He has over 430 publications on primary immunodeficiency, has co-authored important multi-centerpublications on cohorts of children with rare primary immunodeficiencies following HSCT, and has contributed to chapters in several major textbooks. He has also co-authored national guidelines on use of irradiated blood products in patients with primary immunodeficiency in the UK, guidelines on management of children with 22q11 deletion syndrome, and guidelines on extracorporeal photopheresis for treatment of acute graft versus host disease. He has also written international guidelines for the treatment of DNA repair disorders and CD40 ligand deficiency.